Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
Text
Xeljanz® (tofacitinib) – New indication
May 30, 2018 - The FDA announced the approval of Pfizer’s Xeljanz (tofacitinib), for the treatment of adult patients with moderately to severely active ulcerative colitis (UC).
